Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.66 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | C1R | P00736 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067674 | 0.79 | BACE1 (1.00) | BACE1GRM5KCNH2MAOATYMS | |
| SCHEMBL28415013 | 0.78 | BACE1 (0.64) | BACE1GRM5KCNH2MAOAMAOB | |
| SCHEMBL239860 | 0.78 | CYP1A2 (0.46) | BACE1MAOAMAOBP2RX7C1R | |
| SCHEMBL29746469 | 0.78 | CYP1A2 (0.46) | BACE1MAOAMAOBP2RX7C1R | |
| SCHEMBL13077349 | 0.77 | MAOA (0.41) | BACE1KCNH2MAOAMAOBP2RX7 | |
| SCHEMBL1599253 | 0.76 | BACE1 (0.39) | BACE1MAOAMAOBP2RX7KMT2A | |
| SCHEMBL25213658 | 0.75 | BACE1 (0.37) | BACE1MAOAMAOBCYP1A2CYP3A4 | |
| SCHEMBL116741 | 0.75 | ALDH1A1 (0.50) | BACE1KCNH2MAOAMAOBKMT2A | |
| SCHEMBL1615737 | 0.75 | ACHE (0.45) | BACE1MAOAMAOBP2RX7KMT2A | |
| SCHEMBL3338347 | 0.75 | MAOA (0.40) | BACE1MAOAMAOBP2RX7C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4583874-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2025-07-16 | — | — | EP | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546572-A | Novel naphthyl and isoquinoline sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| US-7049325-B2 | Quinoline derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | BROKA CHRIS A | 2006-04-20 | — | — | US | disclosed |
| CN-1199950-C | Quinolene derivatives as anti-inflammation agents | HOFFMANN LA ROCHE (CH) | 2005-05-04 | — | — | CN | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| CN-1466575-A | Quinoline derivatives as anti-inflammatory agents | - | 2004-01-07 | — | — | CN | disclosed |
| EP-1313707-A1 | QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | SNYTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002012192-A1 | QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | WO | disclosed |
| US-5372813-A | Measurement of serotonin uptake sites in a sample using a radio labeled substituted 6-nitroquipazine as a radioligand | THE REGENTS, UNIVERSITY OF CALIFORNIA (US) | 1994-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | NR5A2, PTGER4, IL5 | BACE1 1633/4885GRM5 82/4885KCNH2 2124/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | BACE1 445/4885GRM5 316/4885KCNH2 650/4885 |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | CNR1, CNR2, PTGER4 | BACE1 1977/4885GRM5 805/4885KCNH2 1642/4885 |
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | BACE1 4670/4885GRM5 3169/4885KCNH2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.